Home

Carlo Fallone

Academic title(s): 

Associate Professor of Medicine, McGill University

Carlo Fallone
Contact Information
Address: 

McGill University Health Center (MUHC)

Glen Site- Royal Victoria Hospital

1001 Blvd Décarie, Rm #: D02.3312

Montreal, Qc, H4A 3J1

Phone: 
514-934-1934 Ext 31616
Position: 
Chair of the Association of Physicians of the MUHC Department of Medicine
Degree(s): 

MD,CM, FRCP(C), AGAF, CAGF

Fellowship Training: 

93-94: Research Fellow: Gastric cytoprotection & H. pylori, Queen’s University

94-95: Research Fellow: H. pylori, McGill University

Areas of expertise: 

· Helicobacter pylori

· Dyspepsia

· Gastroesophageal Reflux Disease

· Colon Cancer

· Gastrointestinal Bleeding

 

Biography: 

Dr. Fallone received his MD degree from the Faculty of Medicine at McGill University. After completing his residency in Gastroenterology and further research training at both McGill and Queen’s Universities, he joined the Gastroenterology Division of the Royal Victoria Hospital (RVH) as a full-time gastroenterologist. He has published over 95 peer-reviewed articles (over 19,000 views and 2800 citations as per Mendeley), 4 book chapters and over 150 abstracts and has lectured widely. He was a recipient of the “Chercheur-boursiers clinicien Junior 1 & 2” research scholar award from the Fonds de la Recherche en Santé du Québec.

Dr. Fallone is currently the Chair of the Association of Physicians of the MUHC Department of Medicine. He was Site Director of the Gastroenterology Division of the RVH at the MUHC from 2001-2007. At the provincial level, he was an executive-elect member of the Quebec Association of Gastroenterology (2005-2011). Nationally, he is currently serving on the executive governing board of the Canadian Association of Gastroenterology as Vice President- Secretary. He was also VP of Finance (2005-2009), VP of Administrative Affairs (2010-2013) and has actively participated in several initiatives including PAGE/SAGE program, colon cancer surveillance guidelines, RUGBE, GI bleed guidelines, GERD consensus guidelines and just recently published the combined CAG/CHSG Helicobacter pylori consensus guidelines. He is also Vice-President of the Canadian Helicobacter Study Group.

Selected publications: 

Publications: Selected 10 publications in the last 5 years

  1. Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, Fischbach L, Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication (Review). Cochrane Database of Systematic Reviews. 2016 (June); Issue 6: Art. No. CD009034. doi:10.1002/14651858.CD009034. p.1-156.
  2. Fallone CA, Chiba N, Veldhuyzen van Zanten S, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, and Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151:51-69. doi:10.1053/j.gastro.2016.04.006.
  3. Shaikh T, and Fallone CA. Effectiveness of second through sixth line salvage Helicobacter pylori treatment: Bismuth Quadruple therapy is almost always a reasonable choice. Can J Gastroenterol & Hepatol 2016; doi 10.1155/2016/7321574.
  4. Chen Y-I, and Fallone CA. A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a “real world” setting. Can J Gastroenterol & Hepatol 2015; 29: e7-e10.
  5. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication (Review). Cochrane Database Systematic Reviews. 2013Dec; Issue12:CD008337. doi: 10.1002/14651858.CD008337. p. 1-420.
  6. Leddin D, Enns R, Hilsden R, Fallone CA, Rabeneck L, Sadowski DC, Singh H. Colorectal cancer surveillance after index colonoscopy: Guidance from the Canadian Association of Gastroenterology. Can J Gastroenterol 2013; 27: 224-228.
  7. Fallone CA, Barkun AN, Szilagyi A, Herba KM, Sewitch M, Martel M, Fallone SS. Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can J Gastroenterol 2013; 27: 397-402.
  8. Leddin D, Armstrong D, Borgaonkar M, Bridges RJ, Fallone CA, Telford J, Chen Y, Colacino P, Sinclair P. The 2012 SAGE wait times program: Survey of access to gastroenterology in Canada. Can J Gastroenterol 2013; 27: 83- 89.
  9. Soulellis CA, Carpentier S, Chen YI, Fallone CA, Barkun AN. Lower gastrointestinal hemorrhage controlled with endoscopically applied TC-325 (with videos). Gastrointest Endosc 2013; 77: 504-507.
  10. Jones NL, Chiba N, Fallone C, Thomson A, Hunt R, Jacobson K, Goodman K, on behalf of Canadian Helicobacter study group participants. Helicobacter pylori in First Nations and recent immigrant populations in Canada. Can J Gastroenterol 2012; 26: 97-103.









 

Location: 
MUHC, Royal Victoria Hospital
Back to top